Among 2,819 intravenous, intravenous, intramuscular clinical studies (including double-blind trials) in 137 in Japan, the clinical outcomes of 1,409 patients who were able to determine efficacy and were approved for this product were as follows (refractory or severe) Infection, with daily symptoms increased to 4g per day (potency), children increased to 150mg (potency) / kg body weight):
The total effective rate of sepsis caused by Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae was 80.6% (25/31), and the dosage was 2-4 g per day for adults and 50-150 mg/kg for children.
2. Respiratory infection
The total effective rate of respiratory infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella, Proteus, Morganella, and Providence was 79.7% (267/335). The amount of drip or intravenous injection is 2-4g per day. In the double-blind trial, the efficacy of this product has been verified.
3. Biliary infection
This product is excreted in the bile and can reach a higher concentration in the bile. The total effective rate of cholecystitis and cholangitis caused by Escherichia coli and Klebsiella pneumoniae was 83.1% (49/59). The dose is 2-4 g per day.
The total effective rate of peritonitis caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides, and Prevobacter (except for Proviral bacteria) was 87.5% (161/184). Mostly intravenous drip, the dosage is 2-4g per day.
5. Urinary tract infection
The total effective rate of cystitis and pyelonephritis caused by Escherichia coli, Klebsiella, Proteus, Morganus, and Providence was 73.1% (302/413). The dosage is mostly 1-2g per day. The results of a double-blind controlled trial of chronic complex urinary tract infections demonstrate the efficacy of this product.
6. Obstetrics and Gynecology
Vestibular gland inflammation, intrauterine infection, uterus caused by Escherichia coli, Klebsiella pneumoniae, Pseudoproteobacteria, Streptococcus pneumoniae, Bacteroides, and Prevoviruses (except for two-way Prevobacteria) The total effective rate of accessory inflammation and para-uterine tissue inflammation was 94.7% (232/245). The dosage is mostly 2-4g per day.
7. The field of oral surgery
The total effective rate of cellulitis and jawitis caused by Streptococcus pneumoniae was 83.8% (119/142). The amount administered is usually 2-4 g per day.